37 results on '"Soo Young Hur"'
Search Results
2. Postoperative Adjuvant Chemoradiotherapy Versus Chemotherapy Alone for Stage III Endometrial Cancer: A Multicenter Retrospective Study
- Author
-
Ji Geun Yoo MD, Jin Hwi Kim MD, PhD, Chan Joo Kim MD, PhD, Hae Nam Lee MD, PhD, Min Jong Song MD, PhD, Dong Choon Park MD, PhD, Joo Hee Yoon MD, PhD, Sang Il Kim MD, PhD, Soo Young Hur MD, PhD, and Sung Jong Lee MD, PhD
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Introduction We aimed to evaluate the efficacy and toxicity of the combination of 6 cycles of chemotherapy and radiation therapy compared with chemotherapy alone as postoperative adjuvant therapy for patients with stage III endometrial cancer. Methods This retrospective cohort study included patients with stage III endometrial cancer who received postoperative chemoradiotherapy or chemotherapy alone at 6 hospitals between January 2009 and December 2019. The progression-free survival (PFS) and overall survival (OS) for each treatment group were analyzed using the Kaplan–Meier method. We also assessed differences in toxicity profiles between the treatment groups. Results A total of 133 patients met the inclusion criteria. Of these, 80 patients (60.2%) received adjuvant chemoradiotherapy and 53 (39.8%) received chemotherapy alone. The PFS and OS did not differ significantly between the groups. For patients with stage IIIC endometrioid subtype, the chemoradiotherapy group had significantly longer PFS rate than did the chemotherapy alone group (log-rank test, P = .019), although there was no significant difference in the OS (log-rank test, P = .100). CRT was identified as a favorable prognostic factor for PFS in multivariate analysis (adjusted HR, .37; 95% CI, .16-.87; P = .022). Patients treated with chemoradiotherapy more frequently suffered from grade 4 neutropenia (73.8% vs 52.8%; P = .018) and grade 3 or worse thrombocytopenia (36.3% vs 9.4%; P = .001) compared with the chemotherapy alone group. There were no differences between the 2 treatment groups in the frequency of toxicity-related treatment discontinuation or dose reduction. Conclusion We confirmed that chemoradiotherapy yields longer progression-free survival than does chemotherapy alone for patients with stage IIIC endometrioid endometrial cancer, with an acceptable toxicity profile.
- Published
- 2022
- Full Text
- View/download PDF
3. Plasma-derived exosomal miR-4732-5p is a promising noninvasive diagnostic biomarker for epithelial ovarian cancer
- Author
-
Jingjing Liu, Jigeun Yoo, Jung Yoon Ho, Yuyeon Jung, Sanha Lee, Soo Young Hur, and Youn Jin Choi
- Subjects
Exosomes ,Exosomal miRNA profiling ,microRNAs ,Epithelial ovarian cancer ,miR-4732-5p ,Gynecology and obstetrics ,RG1-991 - Abstract
Abstract Background Exosomal miRNAs regulate gene expression and play important roles in several diseases. We used exosomal miRNA profiling to investigate diagnostic biomarkers of epithelial ovarian cancer (EOC). Methods In total, 55 individuals were enrolled, comprising healthy (n = 21) and EOC subjects (n = 34). Small mRNA (smRNA) sequencing and real-time PCR (RT-PCR) were performed to identify potential biomarkers. Receiver operating characteristic (ROC) curves were conducted to determine biomarker sensitivity and specificity. Results Using smRNA sequencing, we identified seven up-regulated (miR-4732-5p, miR-877-5p, miR-574-3p, let-7a-5p, let-7b-5p, let-7c-5p, and let-7f-5p) and two down-regulated miRNAs (miR-1273f and miR-342-3p) in EOC patients when compared with healthy subjects. Of these, miR-4732-5p and miR-1273f were the most up-regulated and down-regulated respectively, therefore they were selected for RT-PCR analysis. Plasma derived exosomal miR-4732-5p had an area under the ROC curve of 0.889, with 85.7% sensitivity and 82.4% specificity in distinguishing EOC patients from healthy subjects (p
- Published
- 2021
- Full Text
- View/download PDF
4. Genomic, transcriptomic, and viral integration profiles associated with recurrent/metastatic progression in high‐risk human papillomavirus cervical carcinomas
- Author
-
Jing Jing Liu, Jung Yoon Ho, Jung Eum Lee, Soo Young Hur, Jinseon Yoo, Kyu Ryung Kim, Daeun Ryu, Tae Min Kim, and Youn Jin Choi
- Subjects
APOBEC ,cervical cancer ,human papillomavirus ,immunoprofiling ,metastasis ,recurrence ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Acquisition of recurrent/metastatic potential by a tumor cell defines a critical step in malignant progression. However, understanding of metastatic progression at the molecular level is scarce for cervical carcinomas (CES). In this study, we performed genomic, transcriptomic, and viral profiling of five pairs of primary (CES‐P) and matched recurrent/metastatic tumors (CES‐R/M) with high risk human papillomavirus. Whole exome sequencing revealed mutation features of CES‐R/M including elevated mutation burdens and prevalent copy number alterations compared to their matched CES‐P. A relative deficit of APOBEC‐related mutation signatures accompanying the transcriptional downregulation of APOBEC3A was observed for CES‐R/M. Mutations in genes encoding epigenetic regulators were commonly observed as CES‐R/M‐specific alterations. Immunoprofiling and gene set analysis revealed CES‐Ps were enriched with transcripts representing activated anticancer immunity such as interferon‐gamma pathway, while CES‐R/M exhibited upregulation of genes involved in epithelial‐mesenchymal transition and angiogenesis. Viral capture sequencing revealed that integration sites remained enriched in viral E1 protein domain during malignant progression. Moreover, we found transcriptional upregulation of POSTN and downregulation of APOBEC3A were associated with unfavorable clinical outcomes in CES. Comprehensive genomic and transcriptomic profiling of a rare cohort including CES‐R/M identified metastases‐specific features to advance the molecular understanding into CES metastatic progression with potential clinical implications.
- Published
- 2020
- Full Text
- View/download PDF
5. CKD-602, a topoisomerase I inhibitor, induces apoptosis and cell-cycle arrest and inhibits invasion in cervical cancer
- Author
-
Sungha Lee, Jung Yoon Ho, Jing Jing Liu, Hyewon Lee, Jae Young Park, Minwha Baik, Minji Ko, Seon Ui Lee, Youn Jin Choi, and Soo Young Hur
- Subjects
CKD-602 ,Cell cycle arrest ,Cervical cancer ,Topoisomerase inhibitor ,Invasion assay ,Therapeutics. Pharmacology ,RM1-950 ,Biochemistry ,QD415-436 - Abstract
Abstract Background Cervical cancer is the third most common gynecological malignancy. Conventional treatment options are known to be ineffective for the majority of patients with advanced or recurrent cervical cancer. Therefore, novel therapeutic agents for cervical cancer are necessary. In this study, the effects of CKD-602 in cervical cancer were investigated. Methods Three established human, immortalized, cervical cancer cell lines (CaSki, HeLa and SiHa) were used in this study. Following treatment with CKD-602, apoptosis was quantified using fluorescein isothiocyanate Annexin V-FITC and propidium iodide (PI) detection kit and cell cycle analysis was analyzed using fluorescence activated cell sorting (FACS). Transwell chambers were used for invasion assays. Western blot assay was performed to analyze proteomics. CaSki cells were subcutaneously injected into BALB/c-nude mice and cervical cancer xenograft model was established to elucidate the antitumor effect of CKD-602 in vivo. Results Treatment with CKD-602 induced apoptosis and increased expression of the enzyme PARP, cleaved PARP, and BAX. In addition, expression of phosphorylated p53 increased. Cell cycle arrest at G2/M phase and inhibition of invasion were detected after treatment with CKD-602. A significant decrease in cervical cancer tumor volume was observed in this in vivo model, following treatment with CKD-602. Conclusions This is the first report of CKD-602 having an antitumor effect in cervical cancer in both an in vitro and in vivo models. The results of this study indicate that CKD-602 may be a novel potential drug, targeting cervical cancer, providing new opportunities in the development of new therapeutic strategies.
- Published
- 2019
- Full Text
- View/download PDF
6. Risk factors for cytological progression in HPV 16 infected women with ASC-US or LSIL: The Korean HPV cohort
- Author
-
Kyeong A So, Seon Ah Kim, Yoo Kyung Lee, In Ho Lee, Ki Heon Lee, Jee Eun Rhee, Mee Kyung Kee, Chi Heum Cho, Sung Ran Hong, Chang Sun Hwang, Mi Seon Jeong, Ki Tae Kim, Moran Ki, Soo Young Hur, Jong Sup Park, and Tae Jin Kim
- Subjects
papillomaviridae ,smoking ,epidemiology ,Gynecology and obstetrics ,RG1-991 - Abstract
ObjectiveThis study was to identify the risk factors for cytological progression in women with atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesions (LSIL).MethodsWe analyzed data from women infected with the human papillomavirus (HPV) who participated in the Korean HPV cohort study. The cohort recruited women aged 20–60 years with abnormal cervical cytology (ASC-US or LSIL) from April 2010. All women were followed-up at every 6-month intervals with cervical cytology and HPV DNA testing.ResultsOf the 1,158 women included, 654 (56.5%) and 504 (43.5%) women showed ASC-US and LSIL, respectively. At the time of enrollment, 143 women tested positive for HPV 16 (85 single and 58 multiple infections). Cervical cytology performed in the HPV 16-positive women showed progression in 27%, no change in 23%, and regression in 50% of the women at the six-month follow-up. The progression rate associated with HPV 16 infection was higher than that with infection caused by other HPV types (relative risk [RR], 1.75; 95% confidence interval [CI], 1.08–2.84; P=0.028). The cytological progression rate in women with persistent HPV 16 infection was higher than that in women with incidental or cleared infections (P
- Published
- 2018
- Full Text
- View/download PDF
7. Identification of large genomic rearrangement of BRCA1/2 in high risk patients in Korea
- Author
-
Do-Hoon Kim, Hyojin Chae, Irene Jo, Jaeeun Yoo, Hyeyoung Lee, Woori Jang, Joonhong Park, Gun Dong Lee, Dong-Seok Jeon, Keun Ho Lee, Soo Young Hur, Byung Joo Chae, Byung Joo Song, Myungshin Kim, and Yonggoo Kim
- Subjects
BRCA1 ,BRCA2 ,Breast cancer ,Ovarian cancer ,Genetic testing ,Korea ,Internal medicine ,RC31-1245 ,Genetics ,QH426-470 - Abstract
Abstract Background While the majority of germline inactivating mutations in BRCA1/2 are small-scale mutations, large genomic rearrangements (LGRs) are also detected in a variable proportion of patients. However, routine genetic methods are incapable of detecting LGRs, and comprehensive genetic testing algorithm is necessary. Methods We performed multiplex ligation-dependent probe amplification assay for small-scale mutation negative patients at high-risk for LGR, based on previously published LGR risk criteria. The inclusion criteria for the high-risk subgroup were personal history of 1) early-onset breast cancer (diagnosed at ≤36 years); 2) two breast primaries; 3) breast cancer diagnosed at any age, with ≥1 close blood relatives (includes first-, second-, or third-degree) with breast and/or epithelial ovarian cancer; 4) both breast and epithelial ovarian cancer diagnosed at any age; and 5) epithelial ovarian cancer with ≥1 close blood relatives with breast and/or epithelial ovarian cancer. Results Two LGRs were identified. One was a heterozygous deletion of exon 19 and the other was a heterozygous duplication of exon 4–6. The prevalence of LGRs was 7% among Sanger-negative, high-risk patients, and accounted for 13% of all BRCA1 mutations and 2% of all patients. Moreover, LGRs reported in Korean patients, including our 2 newly identified cases, were found exclusively in families with at least one high-risk feature. Conclusions Our result suggests that selective LGR screening for Sanger-negative, high-risk patients is necessary for Korean patients.
- Published
- 2017
- Full Text
- View/download PDF
8. Clinical Significance of an HPV DNA Chip Test with Emphasis on HPV-16 and/or HPV-18 Detection in Korean Gynecological Patients
- Author
-
Min-Kyung Yeo, Ahwon Lee, Soo Young Hur, and Jong Sup Park
- Subjects
Human papillomavirus ,DNA chip ,Hybrid capture 2 ,Cervical intraepithelial neoplasia ,Cervical carcinoma ,Pathology ,RB1-214 - Abstract
Background: Human papillomavirus (HPV) is a major risk factor for cervical cancer. Methods: We evaluated the clinical significance of the HPV DNA chip genotyping assay (MyHPV chip, Mygene Co.) compared with the Hybrid Capture 2 (HC2) chemiluminescent nucleic acid hybridization kit (Digene Corp.) in 867 patients. Results: The concordance rate between the MyHPV chip and HC2 was 79.4% (kappa coefficient, κ = 0.55). The sensitivity and specificity of both HPV tests were very similar (approximately 85% and 50%, respectively). The addition of HPV result (either MyHPV chip or HC2) to cytology improved the sensitivity (95%, each) but reduced the specificity (approximately 30%, each) compared with the HPV test or cytology alone. Based on the MyHPV chip results, the odds ratio (OR) for ≥ high-grade squamous intraepithelial lesions (HSILs) was 9.9 in the HPV-16/18 (+) group and 3.7 in the non-16/18 high-risk (HR)-HPV (+) group. Based on the HC2 results, the OR for ≥ HSILs was 5.9 in the HR-HPV (+) group. When considering only patients with cytological diagnoses of “negative for intraepithelial lesion or malignancy” and “atypical squamous cell or atypical glandular cell,” based on the MyHPV chip results, the ORs for ≥ HSILs were 6.8 and 11.7, respectively, in the HPV-16/18 (+) group. Conclusions: The sensitivity and specificity of the MyHPV chip test are similar to the HC2. Detecting HPV-16/18 with an HPV DNA chip test, which is commonly used in many Asian countries, is useful in assessing the risk of high-grade cervical lesions.
- Published
- 2016
- Full Text
- View/download PDF
9. Inhibition of Phosphatidylinositol 3-kinase (PI3K) Signaling Synergistically Potentiates Antitumor Efficacy of Paclitaxel and Overcomes Paclitaxel-Mediated Resistance in Cervical Cancer
- Author
-
Jing Jing Liu, Jung Yoon Ho, Hye Won Lee, Min Wha Baik, Oyoung Kim, Youn Jin Choi, and Soo Young Hur
- Subjects
cervical cancer ,combination therapy ,paclitaxel resistance ,cell cycle ,invasion ,PI3K inhibitor ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Acquired paclitaxel (PTX) resistance limits its effectiveness and results in advanced cancer progression. This review investigated whether the inhibition of phosphatidylinositol 3-kinase (PI3K) signaling overcomes paclitaxel resistance in cervical cancer. It was established paclitaxel-resistant cell lines (PTX-R ME180/PTX-R HeLa) and determined the combination index for paclitaxel and PI3K inhibitors (BYL-719/ LY294002) by tetrazolium dye assay. Flow cytometry was used to detect the cell cycle and apoptosis. Migration and invasion were explored by wound healing and transwell assays. Genes related to multiple pathways were assessed by a western blot. It was found that the PI3K pathway was significantly activated in paclitaxel-resistant HeLa and ME180 cells compared to parental cells. PTX + PI3K inhibitor combined therapy showed a synergistic effect by strengthening paclitaxel-induced S and G2M arrest in PTX-R cell sublines by the inactivation of cyclin A1, cyclin B1, cyclin E, and Cdc2 expression. Moreover, combination therapy significantly enhanced drug sensitivity and apoptosis through the activation of Bax, and cleavage of poly-(ADP-ribose) polymerase compared with paclitaxel alone. In addition, PI3K inhibition also suppressed tumor migration and invasion by targeting β-catenin and matrix metalloproteinase-2/9. The authors suggest that the combination of a PI3K inhibitor with paclitaxel may enhance antitumor activity through a cascade of PI3K signaling events.
- Published
- 2019
- Full Text
- View/download PDF
10. A phase 1/2a, dose-escalation, safety, and preliminary efficacy study of the RKP00156 vaginal tablet in healthy women and patients with cervical intraepithelial neoplasia 2.
- Author
-
Hyun-Woong Cho, Sohyeon Jeong, Seung Hun Song, Young Tae Kim, Jae-Weon Kim, Chi-Heum Cho, Soo Young Hur, Suk-Joon Chang, Yong Man Kim, and Jae Kwan Lee
- Subjects
CERVICAL intraepithelial neoplasia ,WOMEN patients ,HUMAN papillomavirus ,VIRAL load ,STATISTICAL power analysis - Abstract
Objective: This study aimed to determine the safety and efficacy of the RKP00156 vaginal tablet, a CDK9 inhibitor, in healthy women and patients with cervical intraepithelial neoplasia grade 2 (CIN2). Methods: We conducted a phase 1/2a clinical trial of RKP00156. In step 1, RKP00156 at a dose of 10, 25, or 50 mg or a placebo tablet was administered transvaginally to 24 healthy women. In step 2, RKP00156 at a dose of 10, 25, or 50 mg or a placebo tablet was administered once daily for 4 weeks in 62 patients with CIN2. The primary endpoints of this trial were the safety of RKP00156 and the change in the human papillomavirus (HPV) viral load. Results: A total of 86 patients were enrolled and randomized. RKP00156 administration did not cause serious drug-associated adverse events (AEs). Although no significant difference in the HPV viral load was found between the experimental and placebo groups, a reduction in the HPV viral load was observed in the 25 mg-dose group (-98.61%; 95% confidence interval=-99.83%, 4.52%; p=0.046) after treatment completion in patients with a high HPV viral load, despite a lack of statistical power. No differences in histologic regression and HPV clearance were observed. Conclusion: The safety of RKP00156 was proved with no serious AEs. Although the study did not show any significance in histologic regression and HPV clearance, our findings indicate that RKP00156 may have a possibility of short-term inhibitory effect on HPV replication in patients with higher viral loads. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Comparison of ovarian cancer patients and people with familial history of ovary/breast cancer for finding ovarian cancer risk factors.
- Author
-
Youn Jin Choi, Seong Eun Bak, Min Yeop Whang, and Soo Young Hur
- Subjects
OVARIAN cancer ,BREAST cancer ,DISEASE risk factors ,CANCER patients ,BRCA genes - Abstract
Objective: Risk of developing ovarian cancer increases if there is a family history of ovarian cancer or breast cancer, and one of the causes is mutation in the BRCA1 or BRCA2 genes. Therefore, people with a family history of ovarian cancer or breast cancer may undergo BRCA1/2 genetic testing to prevent ovarian cancer, and if a mutation is discovered, they visit clinic more often than those who do not. However, there are many cases where ovarian cancer occurs even when gene mutations are not identified, we investigate to find factors that affect the development of ovarian cancer other than the BRCA1/2 genes. Methods: We reviewed anonymized data of ovarian cancer 2,176 patients and healthy 273 subjects from clinical data warehouse for finding ovarian cancer risk factor. Familial history, age at menarche, menopause status, pregnancy history, and BRCA1, BRCA2 mutations were also analyzed. Results: In univariate analysis, significant variables with p<0.05 were identified as factors such as number of family cancers(breast/ovary/pancreas), BRCA1 mutant and variants of uncertain significance (VUS), number of BRCA family cancers, pregnancy history, and body mass index 23 kg/m² or higher. When multivariate analysis was performed using the stepwise method, number of family cancers(breast/ovary/pancreas), BRCA1 mutant, and VUS were confirmed as meaningful results. Conclusion: Therefore, continuous follow-up will be necessary for the healthy people with not only for the number of family cancers but also for BRCA1/2 VUS. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Clinical Implications of Circulating Tumor DNA from Ascites and Serial Plasma in Ovarian Cancer.
- Author
-
Mi-Ryung Han, Sug Hyung Lee, Jung Yoon Park, Hyosun Hong, Jung Yoon Ho, Soo Young Hur, and Youn Jin Choi
- Subjects
CIRCULATING tumor DNA ,CA 125 test ,PARACENTESIS ,OVARIAN epithelial cancer ,ASCITES ,GENETIC mutation ,BLOOD proteins ,OVARIAN cancer - Abstract
Purpose: The purpose of this study was to identify the clinical utility of circulating tumor DNA (ctDNA) from ascites and serial plasma samples from epithelial ovarian cancer (EOC) patients. Materials and Methods: Using targeted next-generation sequencing, we analyzed a total of 55 EOC samples including ctDNA from ascites and serial plasma and gDNA from tumor tissues. Tumor tissues and ascites were collected during debulking surgeries and plasma samples were collected before and after the surgeries. Because one EOC patient underwent secondary debulking surgery, a total of 11 tumor tissues, 33 plasma samples, and 11 ascites samples were obtained from the 10 patients. Results: Of the 10 patients, nine (90%) contained somatic mutations in both tumor tissues and ascites ctDNA. This mutational concordance was confirmed through correlation analysis. The mutational concordance between ascites and tumor tissues was valid in recurrent/progressive ovarian cancer. TP53was the most frequently detected gene with mutations. ctDNA from serial plasma samples identified EOC progression/recurrence at a similar time or even more rapidly than cancer antigen 125, an established serum protein tumor marker for EOC. Conclusion: Our data suggest that ascites ctDNA can be used to identify the mutational landscape of ovarian cancer for therapeutic strategy planning. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
13. Clinical impact of boost irradiation to pelvic lymph node in uterine cervical cancer treated with definitive chemoradiotherapy.
- Author
-
Kyu Hye Choi, Ji Yoon Kim, Dong Soo Lee, Yun Hee Lee, Sea-Won Lee, Soo Yoon Sung, Hee Hyun Park, Sei-Chul Yoon, Soo Young Hur, Jong-Sup Park, Yeon Sil Kim, Choi, Kyu Hye, Kim, Ji Yoon, Lee, Dong Soo, Lee, Yun Hee, Lee, Sea-Won, Sung, SooYoon, Park, Hee Hyun, Yoon, Sei-Chul, and Hur, Soo Young
- Published
- 2018
- Full Text
- View/download PDF
14. An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021).
- Author
-
Shin-Wha Lee, Yong-Man Kim, Chi Heum Cho, Young Tae Kim, Seok Mo Kim, Soo Young Hur, Jae-Hoon Kim, Byoung-Gie Kim, Seung-Cheol Kim, Hee-Sug Ryu, and Soon Beom Kang
- Subjects
PACLITAXEL ,OVARIAN cancer treatment ,CARBOPLATIN ,PERIPHERAL neuropathy ,PROGRESSION-free survival - Abstract
Purpose Genexol-PM is a biodegradable cremophor EL-free polymeric micelle formulation of paclitaxel. Here, we compared efficacy and safety of Genexol-PM plus carboplatin versus Genexol plus carboplatin for ovarian cancer treatment. Materials and Methods In this multicenter, randomized, phase II study, patients with International Federation of Gynecology and Obstetrics IC-IV epithelial ovarian cancer were randomly assigned (1:1) to receive Genexol-PM 260 mg/m
2 or Genexol 175 mg/m2 with 5 area under the curve carboplatin every 3 weeks (6 cycles). The primary endpoint was the carbohydrate antigen 125 and Response Evaluation Criteria In Solid Tumor composite overall response rate (ORR). Results Of 131 enrolled patients, 98 were included in intention-to-treat analysis. Mean dosages were 260.00±0.00 mg/m2 Genexol-PM or 174.24±3.81 mg/m2 Genexol. Median followup was 18.0 months (range, 6.1 to 33.8 months). ORR was 88.0% (95% confidence interval [CI], 80.4 to 95.6) with Genexol-PM, and 77.1% (95% CI, 67.1 to 87.1) with Genexol (noninferiority threshold, 16.3%). Median time to progression was 14.8 months (95% CI, 11.3 to 20.2) with Genexol-PM and 15.4 months (95% CI, 13.2 to 29.6) with Genexol (p=0.550). Overall, six patients died. Neutropenia was the most common toxicity (incidences of 86.0% vs. 77.1%, p=0.120). Peripheral neuropathy incidences were 84.0% versus 64.6% (p= 0.148). Peripheral neuropathy of ≥ grade 3 occurred in one patient receiving Genexol. All toxicities were manageable. Conclusion Genexol-PM plus carboplatin as first-line treatment in patients with epithelial ovarian cancer demonstrated non-inferior efficacy and well-tolerated toxicities compared with the standard paclitaxel regimen. Further studies are warranted to optimize the dose and schedule, and to investigate long-term outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
15. Factors associated with participation in cervical cancer screening among young Koreans: a nationwide cross-sectional study.
- Author
-
Ha Kyun Chang, Jun-Pyo Myong, Seung Won Byun, Sung-Jong Lee, Yong Seok Lee, Hae-Nam Lee, Keun Ho Lee, Dong Choon Park, Chan Joo Kim, Soo Young Hur, Jong Sup Park, and Tae Chul Park
- Abstract
Objectives: Despite the possibility of early detection of cervical cancer, participation in screening programmes among young Koreans is low. We sought to identify associations between risk factors and participation in screening for cervical cancer among young Koreans. Design: Nationwide cross-sectional study. Setting: Republic of Korea. Participants: 3734. Main outcome measures: The Korea National Health and Nutrition Examination Survey (KNHANES V: 2010-2012) was used to evaluate factors associated with attendance for cervical cancer screening among women aged 15-39. After excluding those who were previously diagnosed with cervical cancer and those with incomplete responses to questionnaires, a total of 3734 subjects were eligible. Multi-dimensional covariates as potential predictors of cervical cancer screening were adjusted in multiple logistic regression analysis. Results: The participation rate for cervical cancer screening was 46% among women aged 40 or younger. The logistic analyses showed that age, education, total household income, smoking and job status among women aged 15-39 were associated with participation in cervical cancer screening (p<0.05). After age stratification, the associated factors differed by age groups. Moreover, a dose-response between participation in cervical cancer screening and high total household income in the 30-39 age group was seen. Conclusions: Predictive factors differed among young women (aged 15-29 vs 30-39). Thus, age-specific tailored interventions and policies are needed to increase the participation rate in screening for cervical cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
16. Can human papillomavirus (HPV) genotyping classify non-16/18 high-risk HPV infection by risk stratification?
- Author
-
Yeoun Eun Sung, Eun Young Ki, Youn Soo Lee, Soo Young Hur, Ahwon Lee, and Park, Jong Sup
- Subjects
PAPILLOMAVIRUS disease diagnosis ,HUMAN papillomavirus vaccines ,COLPOSCOPY ,GENOTYPES ,PATIENT acceptance of health care ,QUALITY of life - Abstract
Objective: Infection with high-risk genotypes of human papillomavirus (HR-HPV) is the major cause of invasive cervical cancers. HPV-16 and HPV-18 are known to be responsible for two-thirds of all invasive cervical carcinomas, followed by HPV-45, -31, and -33. Current guidelines only differentiate HPV-16/18 (+) by recommending direct colposcopy for treatment. We tried to evaluate whether there are differences in risk among 12 non-16/18 HRHPV genotypes in this study. Methods: The pathology archive database records of 1,102 consecutive gynecologic patients, who had results for cervical cytology and histology and for HPV testing, as determined by HPV 9G DNA chip, were reviewed. Results: Among the 1,102 patients, 346 were non-16/18 HR-HPV (+) and 231 were HPV-16/18 (+). We calculated the odds ratios for ≥cervical intraepithelial neoplasia 2 (CIN 2) of 14 groups of each HR-HPV genotype compared with a group of HR-HPV (-) patients. Based on the odds ratio of each genotype, we divided patients with non-16/18 HR-HPV genotypes (+) into two groups: HPV-31/33/35/45/52/58 (+) and HPV-39/51/56/59/66/68 (+). The age-adjusted odds ratios for ≥CIN 2 of the HPV-31/33/35/45/52/58 (+) and HPV-39/51/56/59/66/68 (+) groups compared with a HR-HPV (-) group were 11.9 (95% CI, 7.6 to 18.8; p<0.001) and 2.4 (95% CI, 1.4 to 4.3; p<0.001), respectively, while that of the HPV-16/18 (+) group was 18.1 (95% CI, 11.6 to 28.3; p=0.003). Conclusion: The 12 non-16/18 HR-HPV genotypes can be further categorized (HPV- 31/33/35/45/52/58 vs. HPV-39/51/56/59/66/68) by risk stratification. The HPV-31/33/35/45/52/58 genotypes might need more aggressive action. Large scale clinical trials or cohort studies are necessary to confirm our suggestion. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
17. Barbed versus conventional 2-layer continuous running sutures for laparoscopic vaginal cuff closure.
- Author
-
Jin Hwi Kim, Seung Won Byun, Jae Yeon Song, Yeon Hee Kim, Hee Joong Lee, Tae Chul Park, Keun Ho Lee, Soo Young Hur, Jong Sup Park, Sung Jong Lee, Kim, Jin Hwi, Byun, Seung Won, Song, Jae Yeon, Kim, Yeon Hee, Lee, Hee Joong, Park, Tae Chul, Lee, Keun Ho, Hur, Soo Young, Park, Jong Sup, and Lee, Sung Jong
- Published
- 2016
- Full Text
- View/download PDF
18. DNA methylation in human papillomavirus-infected cervical cells is elevated in high-grade squamous intraepithelial lesions and cancer.
- Author
-
Mi-Kyung Kim, In-Ho Lee, Ki-Heon Lee, Yoo Kyung Lee, So, Kyeong A., Sung Ran Hong, Chang-Sun Hwang, Mee-Kyung Kee, Jee Eun Rhee, Chun Kang, Soo Young Hur, Jong Sup Park, and Tae-Jin Kim
- Subjects
DNA methylation ,CERVICAL cancer diagnosis ,MEDICAL screening ,CYTOLOGICAL research ,CERVICAL intraepithelial neoplasia ,PAP test - Abstract
Objective: DNA methylation has been shown to be a potential biomarker for early cancer detection. The aim of this study was to evaluate DNA methylation profiles according to liquidbased Pap (LBP) test results and to assess their diagnostic value in a Korean population. Methods: A total of 205 patients with various Papanicolaou test results were enrolled to this study (negative, 26; atypical squamous cells of undetermined significance, 39; low grade squamous intraepithelial lesion, 44; high grade squamous intraepithelial lesion (HSIL), 48; and cancer, 48). DNA methylation analysis of four genes, ADCYAP1 , PAX1 , MAL, and CADM1 , was performed on residual cervical cells from LBP samples using a quantitative bisulfite pyrosequencing method. To evaluate the diagnostic performance of the four methylated genes for cancer detection, receiver operating characteristic (ROC) curves were drawn. Sensitivities and specificities were also tested at cutoffs determined from the ROC curves. Results: Cervical cancer cells showed dramatically increased methylation levels for the four genes analyzed. ADCYAP1 and PAX1 also trended toward elevated methylation levels in HSIL samples, although the levels were much lower than those in cancer cells. The sensitivities of methylated ADCYAP1 , PAX1 , MAL, and CADM1 for the detection of cancer were 79.2%, 75.0%, 70.8%, and 52.1%, and the specificities were 92.0%, 94.0%, 94.7%, and 94.0%, respectively. Methylated ADCYAP1 and PAX1 demonstrated relatively better discriminatory ability than did methylated MAL and CADM1 (area under the curves 0.911 and 0.916 vs. 0.854 and 0.756, respectively). Conclusion: DNA methylation status, especially in the ADCYAP1 and PAX1 genes, showed relatively good specificity, ranging from 90% to 94%. The possible additive and complementary roles of DNA methylation testing with respect to conventional cervical cancer screening programs will need to be validated in prospective population-based studies. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
19. Methylation of Cervical Neoplastic Cells Infected With Human Papillomavirus 16.
- Author
-
Eun Young Ki, Keun Ho Lee, Soo Young Hur, Jee Eun Rhee, Mee Kyung Kee, Chung Kang, and Jong Sup Park
- Published
- 2016
- Full Text
- View/download PDF
20. A Clinicopathological Review of Pulmonary Metastasis from Uterine Cervical Cancer.
- Author
-
Eun Young Ki, Keun Ho Lee, Jong Sup Park, and Soo Young Hur
- Subjects
LUNG diseases ,METASTASIS ,UTERINE cervix incompetence ,MEDICAL records ,HYSTERECTOMY complications ,CANCER chemotherapy - Abstract
Purpose: The purpose of this study was to investigate the clinicopathological features of pulmonary metastasis from cervical cancer. Materials and Methods: We reviewed the medical records of 56 patients with cervical cancer who developed pulmonary metastasis after radical hysterectomy, postoperative concurrent chemoradiation or systemic chemotherapy between January 1990 and March 2014. Results: Fifty-six patients were diagnosed with pulmonary metastasis from cervical cancer. The prevalence of pulmonary metastasis was 3.6%. The mean event-free duration was 12 months. Twelve patients underwent surgical removal of metastatic lesions. The overall survival (OS) of patients with ⩽ 3 metastatic lung lesions was 40.7 months, longer than those with > 4 lesions (25 months, p=0.034). The OS of patients who underwent surgical resection was 53.8 months, longer than that of those who did not (p=0.006). In addition, the OS of patients with adjuvant platinum-based chemotherapy was 32.6 months (p=0.027). Conclusion: In this study, we found that the number of metastatic nodules, surgical resection, and postoperative platinum-based chemotherapy can influence clinical outcome. Further studies on prognostic factors and successful treatment modalities are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
21. Pseudomyxoma peritonei extending to the lower extremity: a case report.
- Author
-
Min Wook Joo, Yang-Guk Chung, Soo Young Hur, Ahwon Lee, Chan Kwon Jung, Won-Hee Jee, and Jong Ho Kim
- Subjects
PERITONEAL cancer ,PERITONEUM tumors ,MUCINS ,ASCITES - Abstract
Pseudomyxoma peritonei is characterized by mucinous ascites originating from a mucin-producing neoplasm; however, even the definition is still under debate. Tumor deposits extend and ultimately engulf the entire cavity, causing death from cachexia due to limited intestinal movement. Here, we report a unique case of an 80-year-old woman with pseudomyxoma peritonei, which extended to the lower extremity mimicking infectious condition. The patient survived for a long time without bowel obstruction despite having the histologic subtype that has an unfavorable prognosis. The extremity lesion was treated with limited extensive surgery. The origin of thediseaseandthemechanism of extension to the extremity could not be clarified. Clinicians should be aware of the original disease entity and this unusual presentation and determine its mechanism and the best management strategy. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
22. Benign metastasizing leiomyoma of the lung.
- Author
-
Eun Young Ki, Seon Jeong Hwang, Keun Ho Lee, Jong Sup Park, and Soo Young Hur
- Subjects
SMOOTH muscle tumors ,LUNG diseases ,BIOPSY ,DISEASE progression ,SURGICAL excision ,OVARIECTOMY - Abstract
Benign leiomyomas of the uterus are uncommonly found in association with benign smooth muscle tumors beyond the confines of the uterus. Benign metastasizing leiomyoma (BML) is a rare disease in which the lung is described to be the most afflicted extrauterine organ. We present a brief review of the literature, along with case reports for four patients who were followed up after resection of a pulmonary lesion or after pathological confirmation by biopsy. The clinical course of BML varies from chronic asymptomatic appearance to rapid progression, leading to respiratory failure and death. Our BML patients did not complain of pulmonary symptoms, such as cough, dyspnea, or chest tightness. Pathology revealed benign leiomyomas with no atypia and mitotic activity <5 per 10 high-power field. Immunohistochemical staining was positive for actin and desmin. A standard treatment for BML has not yet been established. Because of the hormone-sensitive characteristics of BML, treatments are based on hormonal manipulation along with either surgical or medical oophorectomy. Benign metastasizing leiomyoma can be observed in postmenopausal women. We observed four patients who did not receive adjuvant hormonal therapy because they were postmenopausal or perimenopausal. All patients are still healthy and show no evidence of recurrence or progression of the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
23. Adenoma malignum of the uterine cervix: report of four cases.
- Author
-
Eun Young Ki, Seung Won Byun, Jong Sup Park, Sung Jong Lee, and Soo Young Hur
- Subjects
CANCER cells ,ADENOCARCINOMA ,CERVICAL cancer ,HISTOLOGY - Abstract
Adenoma malignum (AM) of the cervix is a rare disease and it is difficult to diagnose due to the deceptively benign appearance of the tumor cells. These lesions have mucin-rich cystic lesions and are usually situated deep in the cervix. Since AM is very rare, standard screening tests, diagnostic tools and treatments have not yet been established. Radiologically, it mimics multiple nabothian cysts as a benign-looking tumor. Histologically, AM is a well-differentiated adenocarcinoma and could be misdiagnosed as a benign lesion. These findings make a preoperative diagnosis of AM difficult and can result in surgery being performed based on a misdiagnosis. We report here on four cases of pathologically confirmed AM. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
24. Laparoscopic upper vaginectomy for post-hysterectomy high risk vaginal intraepithelial neoplasia and superficially invasive vaginal carcinoma.
- Author
-
Youn Jin Choi, Soo Young Hur, Jong Sup Park, and Keun Ho Lee
- Subjects
- *
LAPAROSCOPIC surgery , *HYSTERECTOMY , *CERVICAL intraepithelial neoplasia , *BLOOD loss estimation , *URINARY catheters , *VESICO-ureteral reflux , *VAGINAL fistula , *CYTOLOGICAL research - Abstract
Background: The aim of this study is to describe the feasibility and efficacy of the laparoscopic upper vaginectomy (LUV) in vaginal intraepithelial neoplasia(VAIN) and superficially invasive vaginal carcinoma. Methods: We studied patients with vaginal intraepithelial neoplasia (VAIN) 2, VAIN 3, and superficially invasive vaginal carcinoma after hysterectomy who have been under laparoscopic upper vaginectomy between March 2010 and March 2012. Results: Four patients underwent LUV after hysterectomy for high risk VAIN and early vaginal cancer. The meanage was 50.8 (range 40-56) years; the mean operation time was 162.5 (range 145-205) minutes; and the mean estimated blood loss was 55 (range 20-100) ml. All the patients restituted bladder function after the removal of the foley catheter. Mean hospital stay was 2 days. Two patients had postoperative complications. One patient with warfarin administration had vaginal stump bleeding and another developed vesico-vaginal fistula. Three of the patients had no residual lesion, but 1 patient had VAIN 1 in the resection margin. Colposcopy was followed on all patients and cytology proved no recurrence. Conclusions: LUV after hysterectomy is a feasible procedure and attentively applicable to high risk VAIN or superficially invasive vaginal carcinoma. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
25. Establishment of a Korea HPV cohort study.
- Author
-
Won-Chul Lee, Sae-Young Lee, Yu Jin Koo, Tae-Jin Kim, Soo Young Hur, Sung Ran Hong, Sung Soon Kim, Mee-Kyung Kee, Jee Eun Rhee, Joo Shil Lee, Ho Sun Choi, Chi Heum Cho, Ki Tae Kim, and Jong Sup Park
- Subjects
PAPILLOMAVIRUS diseases ,SQUAMOUS cell carcinoma ,COHORT analysis ,CERVICAL cancer ,CERVIX uteri tumors - Abstract
We have designed a five-year multicentre prospective cohort study in women who are both human papillomavirus (HPV)-positive with either atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesion (LSIL) of cervix. This study aimed to analyze the risk of developing a high-grade squamous intraepithelial lesion (HSIL) from either ASCUS or LSIL in HPV-positive women, so called 'progression' rate, to investigate differences in the progression rates according to HPV type-specific infection, and to evaluate the various factors associated with the persistence or clearance of HPV infection in the Korean population. At present, the study protocol composed of cervical cytology, HPV DNA testing, and questionnaire have been conducted actively since the first participant was enrolled in 2010. This study is the first nationwide Korea HPV cohort study. Our data will provide valuable information about not only the ambiguous cytology results of ASCUS and LSIL but also the effect of the specific HPV type and other various factors on the progression to HSIL. Finally, the results of our study will be helpful and applicable to determine the primary cervical cancer prevention strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
26. Correlation between immunocytochemistry of human papilloma virus L1 capsid protein and behavior of low-grade cervical cytology in Korean women.
- Author
-
Sung Jong Lee, Ah Won Lee, Tae Jung Kim, Jin Hwi Kim, Jeong Hoon Bae, Chung Won Lee, Min Jong Song, Joo Hee Yoon, Soo Young Hur, and Jong Sup Park
- Subjects
PROTEIN metabolism ,CERVICAL intraepithelial neoplasia ,PAPILLOMAVIRUS diseases ,PEARSON correlation (Statistics) ,RESEARCH funding ,CERVIX uteri tumors ,ACADEMIC medical centers ,DISEASE prevalence ,DESCRIPTIVE statistics ,IMMUNOHISTOCHEMISTRY ,DATA analysis software ,DISEASE progression ,REGRESSION analysis - Abstract
Aim: The aim of this study was to evaluate the behavior of low-grade squamous intraepithelial lesion (LSIL) in Korean women infected with human papillomavirus (HPV) in relation to the immunocytochemical detection of the HPV L1 capsid protein. Material and Methods: From January 2006 to December 2007, a total of 353 immunocytochemistry tests were performed on specimens from HPV-infected patients with LSIL. Due to exclusions, the study population was reduced to 318. Subjects were monitored at 4-6 month intervals. The regression, persistence, and progression of the cytologic abnormalities of the 318 cases were compared with the results of HPV L1 capsid protein immunocytochemical detection. Results: Of the 137 patients negative for the HPV L1 capsid protein, 38 (27.7%) showed progression to high-grade lesions, 50 (36.5%) showed persistence, and 49 (35.8%) showed regression to normal cytological features. In contrast, of the remaining 181 patients positive for the HPV L1 capsid protein, 15 (8.3%) showed progression to high-grade lesions, 74 (40.9%) showed persistence, and 92 (50.8%) showed regression. The results of immunocytochemical testing for the HPV L1 capsid protein show a linear association with the progression or regression behavior of low-grade cervical cytology in patients infected with HPV (linear by linear association test, P < 0.05). Conclusion: Immunocytochemical detection of HPV L1 was significantly related with the biological patterns of LSIL in Korean women. Hence, immunocytochemistry for the detection of HPV L1 is beneficial in providing further information for LSIL. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
27. Somatic frameshift mutations of bone morphogenic protein receptor 2 gene in gastric and colorectal cancers with microsatellite instability PARK et al. BMPR2 MUTATIONS IN MSI CANCERS.
- Author
-
SANG WOOK PARK, SOO YOUNG HUR, NAM JIN YOO, and SUG HYUNG LEE
- Subjects
- *
GENETIC mutation , *COLON cancer , *RECTAL cancer , *GASTROINTESTINAL diseases , *CANCER genetics - Abstract
Park SW, Hur SY, Yoo NJ, Lee SH. Somatic frameshift mutations of bone morphogenic protein receptor 2 gene in gastric and colorectal cancers with microsatellite instability. APMIS 2010; 118: 824-9. Mounting evidence exists that perturbation of bone morphogenic protein (BMP) signaling is involved in cancer development, especially in gastrointestinal cancers. However, somatic mutations of the genes encoding BMP and BMP receptors have not yet been discovered in human cancer tissues. By analyzing a public database, we found that BMP receptor 2 ( BMPR2) and BMP1 genes had mononucleotide repeats in their coding sequences that could be mutation targets in cancers with microsatellite instability (MSI). In this study, we analyzed the mutation of BMPR2 and BMP1 genes in gastric (GC) and colorectal cancers (CRC) with MSI [31 GC with high MSI (MSI-H), 13 GC with low MSI (MSI-L), 38 CRC with MSI-H and 15 CRC with MSI-L] by single-strand conformation polymorphism analysis and DNA sequencing. Overall, we found seven frameshift mutations in the BMPR2 gene, but not in the BMP1 gene. The mutations were an identical deletion mutation of one base in the repeats (c.1748delA) that would result in premature stops of the amino acid synthesis (p.Asn583ThrfsX44). The BMPR2 mutations were detected in 6.5% of GC and 13.2% of CRC with MSI-H. All the cancers with the BMPR2 mutation showed loss of BMPR2 expression. Our data indicate that frameshift mutation of BMPR2 gene occurs in GC and CRC with MSI-H, and suggest that the BMPR2 mutation might contribute to cancer pathogenesis by inactivating BMPR2-mediated BMP signaling. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
28. Mutational analysis of hypoxia-related genes HIF1α and CUL2 in common human cancers.
- Author
-
SANG WOOK PARK, NAK GYUN CHUNG, SOO YOUNG HUR, HO SHIK KIM, NAM JIN YOO, and SUG HYUNG LEE
- Subjects
HYPOXEMIA ,GENETIC mutation ,CANCER ,MICROSATELLITE repeats ,GENETIC polymorphisms ,ACUTE leukemia - Abstract
Hypoxia is a general feature of solid cancer tissues. Hypoxia upregulates hypoxia-inducible factor 1α (HIF1α) that transactivates downstream genes and contributes to cancer pathogenesis. HIF1α is upregulated not only by hypoxia but also by genetic alterations in HIF1α-related genes, including VHL. Cullin 2 (CUL2) interacts with the trimeric VHL-elongin B-elongin C complex and plays an essential role in the ubiquitinated degradation of HIF1α. The aim of this study was to explore whether HIF1α and CUL2 genes are somatically mutated, and contribute to HIF1α activation in common human cancers. For this, we have analyzed the coding region of oxygen-dependent degradation domain of HIF1α in 47 colon, 47 gastric, 47 breast, 47 lung, and 47 hepatocellular carcinomas, and 47 acute leukemias by a single-strand conformation polymorphism assay. In addition, we analyzed mononucleotide repeat sequences (A8) in CUL2 in 55 colorectal and 45 gastric carcinomas with microsatellite instability (MSI). We found one HIF1α mutation (p.Ala593Pro) in the hepatocellular carcinomas (1/47; 2.1%), but none in other cancers. We found two CUL2 frameshift mutations in colon cancers (p.Asn292MetfsX20), which were exclusively detected in high MSI cancers (4.9%; 2/41). Our data indicate that somatic mutation of HIF1α is rare in common cancers, and somatic mutation of CUL2 occurs in a fraction of colorectal cancers (colorectal cancers with high MSI). The data suggest that neither HIF1α nor CUL2 mutation may play a central role in HIF1α activation in gastric, colorectal, breast, lung and hepatocellular carcinomas, and acute leukemias. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
29. Relationship of serum antioxidant micronutrients and sociodemographic factors to cervical neoplasia: a case-control study.
- Author
-
HanByoul Cho, Mi Kyung Kim, Jae Kwan Lee, Sung Kyong Son, Kwang-Beom Lee, Jong-Min Lee, Jung Pil Lee, Soo Young Hur, and Jae-Hoon Kim
- Subjects
CASE-control method ,CERVICAL cancer patients ,CERVICAL cancer ,SERUM ,ANTIOXIDANTS ,SOCIODEMOGRAPHIC factors ,CANCER pathophysiology ,CANCER risk factors - Abstract
Background: Although there have been some epidemiological studies on the effects of diet and nutritional status on cervical carcinogenesis, evidence for a protective effect of antioxidant micronutrients against cervical neoplasia is insufficient. The relationship between serum antioxidant micronutrients and sociodemographic factors and the risk of cervical neoplasia was investigated in this multi-center, case-control study. Methods: The study population included women with histopathological diagnosis of cervical intraepithelial neoplasia (CIN) 1 (n=147), CIN 2/3 (n=177), cervical cancer (n=160), and a control group (n=378). Epidemiological data were collected and the serum concentrations of β-carotene, lycopene, zeaxanthin plus lutein, retinol, α-tocopherol, and γ-tocopherol were measured using reverse-phase, gradient high-pressure liquid chromatography. Results: Cervical cancer was found to be associated with older age, increased body mass index, and lower socioeconomic status as measured by education level and income. The mean serum concentrations of β-carotene, lycopene, zeaxanthin plus lutein, retinol, α-tocopherol, and γ-tocopherol of cervical cancer patients were significantly lower than those of control subjects. Odds ratio adjusted for age, smoking status, alcohol consumption, and human papillomavirus infection status revealed a significant gradient of decreasing risk of CIN 1, CIN 2/3, and cervical cancer with increasing serum concentrations of most antioxidant micronutrients. Conclusions: The results of this study show an inverse association between serum antioxidant micronutrient concentrations and the risk of cervical neoplasia. These results suggest that antioxidant micronutrients play a role in the prevention of cervical carcinogenesis. Clin Chem Lab Med 2009;47:1005–12. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
30. Preoperative levels of plasma micronutrients are related to endometrial cancer risk.
- Author
-
NAN-HEE JEONG, EUN-SEOP SONG, JONG-MIN LEE, KWANG-BEOM LEE, MI-KYUNG KIM, YOUNG-MI YUN, JAE-KWAN LEE, SUNG-KYONG SON, JUNG-PIL LEE, JAE-HOON KIM, SOO-YOUNG HUR, and YONG-IL KWON
- Subjects
MICRONUTRIENTS ,NUTRITION ,TRACE element deficiency diseases ,ENDOMETRIAL cancer ,MUCOUS membranes - Abstract
Objective. To examine the relation between the plasma concentration of antioxidant micronutrients and endometrial cancer risk in Korean women. Design. Hospital-based case-control study. Setting. Seven tertiary medical institutes in Korea. Population. Incidence of 28 endometrial cancer cases were identified and 140 age-matched controls selected for the same period.Methods. Preoperative plasma concentrations of β-carotene, lycopene, zeaxanthin plus lutein, retinol, α-tocopherol, and γ-tocopherol were measured by reverse-phase, gradient high-pressure liquid chromatography. Conditional logistic regression was used to evaluate micronutrient effect after adjustment for body mass index (BMI), menopause, parity, oral contraceptive use, smoking status, and alcohol consumption status.Main outcome measures. Effect of micronutrients on endometrial cancer risk.Results. The mean concentration of plasma β-carotene (p=0.001), lycopene (p=0.008), zeaxanthin plus lutein (p=0.031), retinol (p=0.048), and γ-tocopherol (p=0.046) were significantly lower in endometrial cancer patients than in controls. Plasma levels of β-carotene (p for trend=0.0007) and lycopene (p for trend=0.007) were inversely associated with endometrial cancer risk across tertiles. Women in the highest tertile of plasma β-carotene and lycopene had a 0.12-fold (95% confidence intervals (CIs) 0.03-0.48) and 0.15-fold (95% CIs 0.04-0.61) decreased risk of endometrial cancer compared to women in the lowest tertile, respectively. Other micronutrients such as zeaxanthin plus lutein (p for trend=0.142), retinol (p for trend=0.108), α-tocopherol (p for trend=0.322), and γ-tocopherol (p for trend=0.087) showed no association with endometrial cancer risk.Conclusions. Plasma levels of β-carotene and lycopene are inversely associated with the risk of endometrial cancer in Korean women. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
31. Plasma carotenoids, retinol and tocopherol levels and the risk of ovarian cancer.
- Author
-
NAN-HEE JEONG, EUN-SEOP SONG, JONG-MIN LEE, KWANG-BEOM LEE, MI-KYUNG KIM, JI-EUN CHEON, JAE-KWAN LEE, SUNG-KYONG SON, JUNG-PIL LEE, JAE-HOON KIM, SOO-YOUNG HUR, and YONG-IL KWON
- Subjects
CAROTENOIDS ,BIOLOGICAL pigments ,TERPENES ,VITAMIN E ,OVARIAN cancer - Abstract
Objective. We investigated the relation between plasma carotenoids, retinol and tocopherol levels and ovarian cancer risk in Korean women. Design. Hospital-based case-control study. Setting. Six tertiary medical institutes in Korea. Population. Forty-five epithelial ovarian cancers and 135 age-matched controls. Methods. Preoperative plasma concentrations of β-carotene, lycopene, zeaxanthin plus lutein, retinol, α-tocopherol, and γ-tocopherol were measured by reverse-phase, gradient high-pressure liquid chromatography. Main outcome measures. Odds ratios (OR) and 95% confidence intervals (95%CI) were estimated by tertiles to evaluate the effect of micronutrients on endometrial cancer risk after adjustment for body mass (BMI) index, menopause, parity, oral contraceptive use, smoking status, and alcohol consumption status. Results. Women in the highest tertile for β-carotene had 0.12-times the risk of ovarian cancer of in the lowest tertile (OR 0.12; 95%CI 0.04-0.36). Women with the highest tertiles of lycopene (OR 0.09; 95%CI 0.03-0.32), zeaxanthin/lutein (OR 0.21; 95%CI 0.09-0.52), retinol (OR 0.45; 95%CI 0.21-0.98), α-tocopherol (OR 0.23; 95%CI 0.10-0.53) and γ-tocopherol (OR 0.28; 95%CI 0.11-0.70) had lower risk of ovarian cancer than women in the lowest tertiles. Results were consistent across strata of socio-epidemiologic factors. Conclusions. Micronutrients, specifically ss-carotene, lycopene, zeaxanthin, lutein, retinol, α-tocopherol, and γ-tocopherol, may play a role in reducing the risk of ovarian cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
32. AAC-11 Overexpression Induces Invasion and Protects Cervical Cancer Cells from Apoptosis.
- Author
-
Jin Woo Kim, Hyun Suk Cho, Jeong Hyun Kim, Soo Young Hur, Tae Eung Kim, Joon Mo Lee, In-Kyung Kim, and Sung Eun Namkoong
- Published
- 2000
- Full Text
- View/download PDF
33. Synchronous clear cell adenocarcinoma of the cervix and endometrioid carcinoma of the endometrium.
- Author
-
Sung Taek Park, Min Jong Song, Chung Won Lee, Ah Won Lee, Soo Young Hur, and Jong Sup Park
- Abstract
The article presents a case study of a 54-year-old woman who presented with intermittent vaginal bleeding. She was diagnosed with cervical clear cell carcinoma and endometrial adenocarcinoma. The endometrial adenocarcinoma was revealed during a pelvic computed tomography (CT) and magnetic resonance imaging (MRI) scan. She undergoes concurrent chemoradiation therapy (CCRT) with a cisplatin regimen.
- Published
- 2011
34. Somatic mutation of GNAQ gene is rare in common solid cancers and leukemias.
- Author
-
HYEON SEOK EOM, MIN SUNG KIM, SOO YOUNG HUR, NAM JIN YOO, and SUG HYUNG LEE
- Subjects
LETTERS to the editor ,GENETIC mutation - Abstract
A letter to the editor is presented in response to an article related to rarity of the somatic mutation of G-alpha-q (GNAQ) gene in common solid cancers and leukemias that was published in a previous issue.
- Published
- 2009
- Full Text
- View/download PDF
35. GX-188E DNA vaccine plus pembrolizumab in HPV 16- and/or 18-positive recurrent or advance cervical cancer: a phase 2 trialResearch in context
- Author
-
Myong Cheol Lim, Youn Jin Choi, Soo-Young Hur, Yong-Man Kim, Jae Hong No, Byoung-Gie Kim, Chi Heum Cho, Sung Hoon Kim, Dae Hoon Jeong, Jae-Kwan Lee, Ji Hyun Kim, Yoon-Jeong Choi, Jung Won Woo, Young Chul Sung, and Jong Sup Park
- Subjects
Cervical cancer ,DNA vaccine ,HPV ,Pembrolizumab ,Overall survival ,Medicine (General) ,R5-920 - Abstract
Summary: Background: In an interim analysis of this phase 2 trial, adding the GX-188E vaccine to pembrolizumab resulted in manageable toxicity with antitumor activities in patients with recurrent or advanced cervical cancer. Here, we report the final safety and efficacy results after a long-term follow-up at the study's completion. Methods: This open-label, single-arm, phase II trial was conducted in nine hospitals in South Korea (ClinicalTrials.gov identifier, NCT03444376). Eligible patients were aged ≥18 years with recurrent or advanced inoperable cervical cancer, Eastern Cooperative Oncology Group Performance status of 0 or 1, and positivity for HPV 16/18, who failed the available standard-of-care therapy. Patients received intramuscular 2 mg GX-188E at weeks 1, 2, 4, 7, 13, 19, and 46 and intravenous 200 mg pembrolizumab every 3 weeks for up to 2 years or until disease progression. The primary endpoint was the objective response rate (ORR) within 24 weeks. Findings: Between June 19, 2018, and December 24, 2021, 65 patients were enrolled and received at least one dose of the study treatment. Sixty patients received combination treatment with GX-188E and pembrolizumab and underwent efficacy analysis. After a median follow-up of 14.72 months, the confirmed ORR was 35.0% (95% CI, 23.1–48.4). Five patients (8.3%) had a complete response, and 16 (26.7%) had a partial response. In addition, patients with PD-L1-positive and PD-L1-negative tumors had an ORR of 38.9% (95% CI, 23.1–56.5) and 29.2% (95% CI, 12.6–51.1), respectively. The median duration of response of all the patients was 12.3 months (95% CI, 5.3–not reached [NR]). For those with PD-L1-positive tumors, it was 12.3 months (95% CI, 3.5–NR), and for those with PD-L1-negative tumors, it was NR (95% CI, 2.4–NR). The median progression-free survival of the 60 patients was 4.4 months (95% CI, 2.1–8.3), and the median overall survival was 23.8 months (95% CI, 14.0–NR). 22 (33.8%) of 65 patients had treatment-related adverse events (TRAEs) of any grade and four (6.2%) had grade 3–4 TRAEs. No treatment-related deaths occurred. Interpretation: The GX-188E vaccine combined with pembrolizumab in recurrent or advanced HPV-positive cervical cancer was safe and showed a promising overall survival and clinical response rate. This combination therapy might provide a new potential treatment option for patients with recurrent or advanced cervical cancer. Funding: National Cancer Center Onco-Innovation Unit, Korea.
- Published
- 2024
- Full Text
- View/download PDF
36. Absence of oncogenic AKT1 E17K mutation in prostate, esophageal, laryngeal and urothelial carcinomas, hepatoblastomas, gastrointestinal stromal tumors and malignant meningiomas.
- Author
-
HYEON SEOK EOM, MIN SUNG KIM, SOO YOUNG HUR, NAM JIN YOO, and SUG HYUNG LEE
- Subjects
LETTERS to the editor ,CANCER - Abstract
A letter to the editor is presented in response to an article on the absence of oncogenic AKT1 E17K mutation in prostate, esophageal, laryngeal and urothelial carcinomas, hepatoblastomas, gastrointestinal stromal tumors and malignant meningiomas that was published in a previous issue is presented.
- Published
- 2009
- Full Text
- View/download PDF
37. Correlation between the Digital Cervicography and Pathological Diagnosis Performed at Private Clinics in Korea
- Author
-
Seog-Nyeon Bae, Jin-Hwi Kim, Chung-Won Lee, Min-Jong Song, Eun-Kyung Park, Yong-Seok Lee, Keun-Ho Lee, Soo-Young Hur, Joo-Hee Yoon, Sung-Jong Lee
- Subjects
Medicine - Abstract
Objective: To evaluate the correlation tendency between abnormal findings of digital cervicography and cervical pathology at private clinics in Korea.Methods: Abnormal finding of digital cervicography performed at private clinics in Korea between January 1, 2010 and May 31, 2012 were analysed retrospectively. The patient's age, abnormal findings of digital cervicography, cervical cytology, human papillomaviru (HPV) test and cervical pathology were investigated and the rate of agreement between abnormal finding of digital cervicography and cervical pathology results was calculated. Abnormal findings of digital cervicography were divided into 4 categories: atypical, compatible with CIN1, compatible with CIN2/3 and compatible with cancer.Results: The study group was composed of 1547 women with a mean (range) age of 37.4 (14-91 years). The agreement rate between abnormal findings of digital cervicography and cervical pathology was 52.0% in “compatible with CIN1”, 78.9% in “compatible with CIN2/3”, and 90.2% in “compatible with cancer”.Conclusions: Abnormal findings of digital cervicography were highly concordant with cervical intraepithelial neoplasia (CIN) and cancer examined at outpatient clinics in Korea. Therefore, abnormal interpretations of digital cervicography can be used as an excellent auxiliary technique with cervical cytology for CIN and cancer.
- Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.